-Network: (11 - Statement - Statement Of Income Alternative)

-Income Statement [Abstract] {ID1}

-Statement [Table] {ID2}

-Statement [Line Items] {ID3}

-Revenues: {ID4}

Product net sales {ID5}

Other revenues {ID6}

Total revenues {ID7}

-Operating costs and expenses: {ID8}

Cost of sales (excludes amortization of acquired intangible assets) {ID9}

Selling, general and administrative {ID10}

Research and development {ID11}

Amortization of acquired intangible assets {ID12}

Restructuring charges {ID13}

Operating income {ID14}

-Non-operating income (expense): {ID15}

Interest income {ID16}

Interest expense {ID17}

Unrealized loss on derivative instruments, net {ID18}

Other, net {ID19}

Nonoperating Income (Expense), Total {ID20}

Earnings before income taxes {ID21}

Provision for income taxes {ID22}

Net earnings {ID23}

Net earnings attributable to noncontrolling interest {ID24}

Net earnings attributable to Allergan, Inc. {ID25}

-Earnings per share attributable to Allergan, Inc. stockholders: {ID26}

Basic {ID27}

Diluted {ID28}

-Network: (12 - Statement - Statement Of Financial Position Classified)

-Statement of Financial Position [Abstract] {ID29}

-Statement [Table] {ID30}

-Statement [Line Items] {ID31}

-ASSETS {ID32}

-Current assets: {ID33}

Cash and equivalents {ID34}

Trade receivables, net {ID35}

Inventories {ID36}

Other current assets {ID37}

Total current assets {ID38}

Investments and other assets {ID39}

Property, plant and equipment, net {ID40}

Goodwill {ID41}

Intangibles, net {ID42}

Total assets {ID43}

-LIABILITIES AND EQUITY {ID44}

-Current liabilities: {ID45}

Notes payable {ID46}

Accounts payable {ID47}

Accrued compensation {ID48}

Other accrued expenses {ID49}

Income taxes {ID50}

Total current liabilities {ID51}

Long-term debt {ID52}

Long-term convertible notes {ID53}

Deferred tax liabilities {ID54}

Other liabilities {ID55}

Commitments and contingencies {ID56}

-Equity: {ID57}

-Allergan, Inc. stockholders' equity: {ID58}

Preferred stock, $.01 par value; authorized 5,000,000 shares; none issued {ID59}

Common stock, $.01 par value; authorized 500,000,000 shares; issued 307,512,000 shares as of June 30, 2009 and December 31, 2008 {ID60}

Additional paid-in capital {ID61}

Accumulated other comprehensive loss {ID62}

Retained earnings {ID63}

Stockholders Equity Subtotal Before Treasury Stock, Total {ID64}

Less treasury stock, at cost (3,331,000 shares as of June 30, 2009 and 3,424,000 shares as of December 31, 2008) {ID65}

Total stockholders' equity {ID66}

Noncontrolling interest {ID67}

Total equity {ID68}

Total liabilities and equity {ID69}

-Network: (14 - Statement - Statement Of Cash Flows Indirect)

-Statement of Cash Flows [Abstract] {ID80}

-Statement [Table] {ID81}

-Statement [Line Items] {ID82}

-Cash flows from operating activities: {ID83}

Net earnings {ID84}

-Non-cash items included in net earnings: {ID85}

Depreciation and amortization {ID86}

Amortization of original issue discount and debt issuance costs {ID87}

Amortization of net realized gain on interest rate swap {ID88}

Deferred income tax benefit {ID89}

Loss on disposal and impairment of assets {ID90}

Loss on extinguishment of convertible debt {ID91}

Unrealized loss on derivative instruments {ID92}

Expense of share-based compensation plans {ID93}

Restructuring charges {ID94}

-Changes in assets and liabilities: {ID95}

Trade receivables {ID96}

Inventories {ID97}

Other current assets {ID98}

Other non-current assets {ID99}

Accounts payable {ID100}

Accrued expenses {ID101}

Income taxes {ID102}

Other liabilities {ID103}

Net cash provided by operating activities {ID104}

-Cash flows from investing activities: {ID105}

Acquisitions, net of cash acquired {ID106}

Additions to property, plant and equipment {ID107}

Additions to capitalized software {ID108}

Additions to intangible assets {ID109}

Contractual purchase price adjustments to prior acquisitions {ID110}

Proceeds from sale of business and assets {ID111}

Proceeds from sale of property, plant and equipment {ID112}

Net cash used in investing activities {ID113}

-Cash flows from financing activities: {ID114}

Dividends to stockholders {ID115}

Repayments of convertible borrowings {ID116}

Payments to acquire treasury stock {ID117}

Net borrowings (repayments) of notes payable {ID118}

Sale of stock to employees {ID119}

Excess tax benefits from share-based compensation {ID120}

Net cash used in financing activities {ID121}

Effect of exchange rate changes on cash and equivalents {ID122}

Net increase (decrease) in cash and equivalents {ID123}

Cash and equivalents at beginning of period {ID124}

Cash and equivalents at end of period {ID125}

-Supplemental disclosure of cash flow information {ID126}

-Cash paid for: {ID127}

Interest (net of amount capitalized) {ID128}

Income taxes, net of refunds {ID129}

-Network: (15 - Disclosure - Notes to Financial Statements)

-Notes to Financial Statements [Abstract] {ID130}

Supplemental Cash Flow Note {ID131}

Note 1: Basis of Presentation {ID132}

Note 2: Aczone Asset Purchase {ID133}

Note 3: Restructuring Charges and Integration and Transition Costs {ID134}

Note 4: Intangibles {ID135}

Note 5: Inventories {ID136}

Note 6: Convertible Notes {ID137}

Note 7: Income Taxes {ID138}

Note 8: Share-Based Compensation {ID139}

Note 9: Employee Retirement and Other Benefit Plans {ID140}

Note 10: Legal Proceedings {ID141}

Note 11: Contingencies {ID142}

Note 12: Guarantees {ID143}

Note 13: Product Warranties {ID144}

Note 14: Earnings Per Share {ID145}

Note 15: Comprehensive Income {ID146}

Note 16: Financial Instruments {ID147}

Note 17: Fair Value Measurements {ID148}

Note 18: Business Segment Information {ID149}

Note 19: Subsequent Events {ID150}

ALLERGAN INC XBRL Taxonomy Presentation Networks